Literature DB >> 6185571

Alveolar macrophages in pulmonary immune responses. I. Role in the initiation of primary immune responses and in the selective recruitment of T lymphocytes to the lung.

C R Lyons, M F Lipscomb.   

Abstract

Antigen inoculated intratracheally (IT) into animals can induce primary immune responses and selectively recruit specific T cells to the lung. In the current study, the role of alveolar macrophages (AM) in these two responses was investigated. Antigen-pulsed bronchoalveolar cells (BAC) inoculated IT into guinea pigs generated a population of immune T cells that proliferated in vitro on reexposure to antigen-pulsed macrophages (Mø). The possibility that antigen-pulsed donor BAC shed antigen that was subsequently processed and presented by host Mø was ruled out by genetic experiments. Thus, peritoneal exudate lymphocytes (PEL) from (2 X 13)F1 guinea pigs primed with antigen-pulsed BAC from strain 2 animals responded preferentially to antigen-pulsed strain 2 Mø rather than to antigen-pulsed strain 13 Mø. In a second set of studies, antigen-pulsed BAC inoculated IT into guinea pigs selectively recruited antigen-specific T cells to the lung. Genetic experiments verified that inoculated BAC were the source of the antigen-presenting cells responsible for selective recruitment. Thus, antigen-pulsed strain 2 BAC inoculated IT recruited a greater proportion of (2 X 13)F1 T cells that recognized antigen in the context of strain 2 Mø than F1 T cells that recognized antigen on strain 13 Mø. Taken together, these studies suggest that AM contribute to the regulation of pulmonary immunity by both inducing T lymphocyte immunity and selectively recruiting specific T cells to the lung.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6185571

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Effects of alveolar macrophage depletion on liposomal vaccine protection against respiratory syncytial virus (RSV).

Authors:  A Benoit; Y Huang; J Proctor; G Rowden; R Anderson
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

2.  Expression of surface antigens distinguishing "naive" and previously activated lymphocytes in bronchoalveolar lavage fluid.

Authors:  S Dominique; F Bouchonnet; J M Smiéjan; A J Hance
Journal:  Thorax       Date:  1990-05       Impact factor: 9.139

3.  Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract.

Authors:  A I Bot; T E Tarara; D J Smith; S R Bot; C M Woods; J G Weers
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

Review 4.  Immunopathogenesis in tuberculosis, Part I: Cellular mechanisms of resistance.

Authors:  V Seth; U Singh
Journal:  Indian J Pediatr       Date:  1987 May-Jun       Impact factor: 1.967

5.  The migration of bronchoalveolar macrophages into hilar lymph nodes.

Authors:  D Corry; P Kulkarni; M F Lipscomb
Journal:  Am J Pathol       Date:  1984-06       Impact factor: 4.307

6.  Persistence of influenza as an immunogen in pulmonary antigen-presenting cells.

Authors:  M F Lipscomb; D Yeakel-Houlihan; C R Lyons; R R Gleason; J Stein-Streilein
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

7.  Enhanced alveolar macrophage-mediated antigen-induced T-lymphocyte proliferation in sarcoidosis.

Authors:  A Venet; A J Hance; C Saltini; B W Robinson; R G Crystal
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

8.  Characterization of murine lung dendritic cells: similarities to Langerhans cells and thymic dendritic cells.

Authors:  A M Pollard; M F Lipscomb
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

9.  Dendritic cells with antigen-presenting capability reside in airway epithelium, lung parenchyma, and visceral pleura.

Authors:  K Sertl; T Takemura; E Tschachler; V J Ferrans; M A Kaliner; E M Shevach
Journal:  J Exp Med       Date:  1986-02-01       Impact factor: 14.307

10.  Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model.

Authors:  Elizabeth B Norton; John D Clements; Thomas G Voss; Lucia Cárdenas-Freytag
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.